Business & Economy
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Source: Business News · Published
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Related stories
The Bottom Line
How easy is it to build a business after serving time in jail?
feeds.bbci.co.uk ·
Poundland's future hangs in the balance as chain edges towards collapse
Poundland's bosses is filing a notice of intention to appoint administrators to the business.
feeds.bbci.co.uk ·
UK government borrowing costs fall as City welcomes ‘no harm’ budget – business live
Premier owner Whitbread says budget business rate measures ‘will do much to mitigate’ damage of past two budgets to hospitality sector The Institute for Fiscal Studies said Wednesday’s budget was “broadly the budget that many people were expecting”. IFS director Helen Miller told
Business | The Guardian ·
I earn £30,000. I'm angry there was no fuel duty cut in the Budget
People on a range of incomes from £4,062 to £150,000 a year tell the BBC what they made of this year's Budget.
feeds.bbci.co.uk ·
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Business News ·